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Lewis Y (LeY) antigen is highly expressed in a variety of human carcinomas of epithelial cell origin. Recent studies suggest functional
blockade of LeY may provide a novel therapeutic approach for the treatment of cancers. However, suppressing LeY expression by genetic
manipulation and its impact on neoplastic cell proliferation has not been investigated. We report here that different fucosyltransferases (FUTs)
were expressed with the greatest expression of fucosyltransferase I or IV (FUT1/4), the two key enzymes for the synthesis of LeY in human
epidermoid carcinoma A431 cells. Knocking down FUT1/4 expression by short interfering RNA technique dramatically reduced the expression of
FUT1/4 and LeY and inhibited cell proliferation through decreasing epidermal growth factor receptor (EGFR) signaling pathway. Treatment of
A431 cells that were inoculated into the nude mice with FUT1 siRNA or FUT4 siRNA greatly impeded tumor growth. Suppressing FUT1/4
expression also blocked EGF-induced tyrosine phosphorylation of EGFR and mitogen-activated protein kinases. In conclusion, suppressing the
expression of FUT1/4 by RNAi technology reduces the synthesis of LeY and inhibits cancer growth. It may serve as a potential methodology for
the treatment of cancers that express LeY glycoconjugates.
© 2007 Elsevier B.V. All rights reserved.Keywords: Fucosyltransferase; siRNA; Tumor growth; Lewis antigen1. Introduction
Lewis Y is carried by glycoconjugates (glycoproteins and
glycolipids) on cell surface. It participates in a variety of phy-
siological and pathological processes in eukaryotic organisms,
including embryo implantation, infection, inflammation and
cancer metastasis [1–4]. Elevated expression of LeYantigen has
been found in 60–90% of the human carcinomas of epithelial
cell origin, such as breast, pancreas, endometrium, ovary, colon,
stomach, urothelium, lung and liver cancers[4–12], and cor-
relates with the enhanced neoplastic cell proliferation, invasion,
metastasis and poor prognosis [4,6,13,14]. Accumulated
evidence suggests that LeY may not only be regarded as a⁎ Corresponding author. Tel.: +86 411 84722083, +86 13500710266; fax: +86
411 84722083.
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doi:10.1016/j.bbamcr.2007.10.007crucial cancer-associated marker, but also as a potential target
for the treatment of LeY-positive cancers.
LeY is a difucosylated oligosaccharide [Fucα1→2Galβ1→4
(Fucα1→3) GlcNAcβ1→R] [15,16]. The two terminal fucosy-
lating reactions of it are catalyzed by the specific fucosyltrans-
ferases (FUTs). FUTs are a group of fucosylation synthases.
By catalyzing the transfer of fucose (Fuc) residue from the
donor substrate, GDP-Fuc, to the oligosaccharide acceptor in
α1, 2-, α1, 3/4-, and α1, 6-linkage, FUTs promote the synthesis
of fucosylated oligosaccharide chain of glycoconjugates [17–
19]. The synthesis of LeY is mainly controlled by an α1, 2-
fucosyltransferase I (FUT1), and an α1, 3-fucosyltransferase IV
(FUT4) [20–23]. Based on type 2 [Galβ1→4GlcNAcβ1→R]
epitope, LeY is synthesized by the addition of a Fuc residue to
galactose (Gal) terminal with theα1, 2 linkage (H type 2 epitope)
and a Fuc residue to N-acetylglucosamine (N-GlcNAc) with
the α1, 3 linkage [24–27].
Table 1





FUT1 442 F: 5′-TGGCCTTCCTGCTAGTCTGT-3′
R: 5′-CTCAAGTCCGCGTACTCCTC-3′
FUT2 342 F: 5′-CTAGCGAAGATTCAAGCCATGTGG-3′
R: 5′-GACGTACTCCCCCGGGATGTG-3′
FUT3 1086 F: 5′-ATGGATCCCCTGGGTGCAGCCAAG-3′
R: 5′-TCAGGTGAACCAAGCCGCTATGCT-3′
FUT4 456 F: 5′-CGGACGTCTTTGTGCCTTAT-3′
R: 5′-CGAGGAAAAGCAGGTACGAG-3′
FUT5 408 F: 5′-CTTATGGCAGTGGAACCTGTCACC-3′
R: 5′-CCAGCCGTAGGGCGTGAAGATGTC-3′
FUT6 963 F: 5′-CCCACTGTGTACCCTAATGGGTCC-3′
R: 5′-CTCTCAGGTGAACCAAGCCGCTAT-3′
FUT7 497 F: 5′-CACCTCCGAGCATCTTCAACTG-3′
R: 5′-CGTTGGTATCGGCTCTCATTCATG-3′
FUT9 460 F: 5′-CATTTGGGCAGACCTTTGACCTTAC-3′
R: 5′-TATTCTCCAAATGCTTGCCCGTAGG-3′
PCNA 651 F: 5′-GCTCCATCCTCAAGAAGGTGTT-3′
R: 5′-TCACCGTTGAAGAGAGTGGAGT-3′
β-actin 838 F: 5′-ATCTGGCACCACACCTTCTACAATGAGCTGCG-3′
R: 5′-CGTCATACTCCTGCCTGCTGATCCACATCTGC-3′
F: forward primer; R: reverse primer.
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carbohydrate antigens is greatly impacted by the aberrant control
of different glycosyltransferases. FUT1 and FUT4 are overex-
pressed in some cancers, e.g., FUT1 in human and rat colon
cancer [28–30], and FUT4 in human colon cancer [31], pan-
creatic cancer [32], gastric cancer [33] and lung adenocarcinoma
[34]. The augmented LeY synthesis in cancers may be caused by
the abnormal expression of FUT1/4. Transfection of mouse or
human FUT1 gene to ovarian carcinoma-derived RMG-1 cells
significantly elevates the expression level of LeY glycolipids,
and stimulated the viability of the transfectants even in the
presence of an anticancer drug [35]. The regulatory role of FUT4
gene expression has not been well elucidated. By developing a
stable FUT4 gene overexpressing A431 cells, we have shown
that FUT4 enhanced synthesis of LeY oligosaccharide which
correlates with the increased cell proliferation [36].
The molecular mechanisms by which LeY causes the
malignancy of cancer cells have not been completely under-
stood. Glycosylation of epidermal growth factor receptor
(EGFR) is important for the binding of EGFR with its ligand
[37,38]. LeYoligosaccharide of EGFR plays a critical role in the
activation of EGFR signaling pathway. Treatment of the cells
with an antibody directed against LeY blocks the activation of
glycosylated EGFR and EGFR mediated mitogen-activated
protein kinase (MAPK) signaling. Anti-LeY antibody binds to
glycosylated EGFR and inhibits cell proliferation [39–41].
In this report, we developed RNA interference-mediated
suppression of FUT1 (EC 2.4.1.69) and FUT4 (EC 2.4.1.152)
expression, and evaluated their impact on LeY expression and
tumor growth. We have also observed the effect of FUT1/4
siRNAs on EGFR/MAPK phosphorylation. These studies
indicates that knocking down FUT1/4 expression in A431
cells decreases LeY expression, inhibites EGF-induced tyrosine
phosphorylation of EGFR and MAPK, which leads to reduced
cell proliferation and tumor growth. To our knowledge, it is the
first time to study the role of genetic manipulation of LeY
expression on tumor growth using both in vivo and in vitro
models. It may contribute to the development of a novel
therapeutic methodology to treat LeY-positive cancers.
2. Materials and methods
2.1. Cell culture
A431 cells obtained from the American Tissue Culture Collection
(Manassas, VA) were maintained in DMEM/F12 (1:1, Invitrogen) supplemented
with 10% fetal bovine serum (FBS), 100 U/ml penicillin, and 50 μg/ml
streptomycin at 37 °C under 5% CO2 in humidified air.
2.2. Generation of FUT1/4 RNA interfering plasmids
siRNA oligomers were designed according to the sequence of human FUT1
gene (GenBank accession number: M35531) and human FUT4 gene (GenBank
accession number: M58596). Using siRNA-designing program (Ambion Inc.),
six potential siRNA oligomers of FUT1/4 with BamHI and HindIII restriction
sites at the 5′ and 3′ ends were developed and commercially generated (Sangon
Company, China). After being analyzed by BLAST search to ensure the
accuracy of each oligomer, the efficiency of these siRNAs in knocking down the
expression of FUT1 or FUT4 was tested by transfection of these siRNAs into
A431 cells. Two siRNAs from each gene group provided the greatest decrease inFUT1 or FUT4 expression. The siRNA sequences were: FUT1-1 siRNA: 5′-
GATCCTGGCCGGTTTGGTAATCAGTTCAAGAGACTGATTAC-
CAAACCGGCCATTA-3′ , 5′-AGCTTAATGGCCGGTTTGGTAAT-
CAGTCTCTTGAACTGATTACCAAACCGGCCAG-3′; FUT1-2 siRNA: 5′-
GATCCAGACTTTGCCCTGCTCACATTCAAGAGATGTGAGCAGGG-
CAAAGTCTTTA-3′, 5′-AGCTTAAAGACTTTGCCCTGCTCACATCTCTT-
GAATGTGAGCAGGGCAAAGTCTG -3 ′ . FUT4-1 siRNA: 5 ′ -
GATCCGCCTGGCAAGTAACCTCTTCTCAAGAGAAAGAGGT-





tides were annealed before cloning into the linearized pSilencer 4.1-CMV
neo-vector using T4 DNA ligase (Takara) per manufacturer's instructions
(Ambion, Inc). The successful ligation was confirmed by BamHI/HindIII
double digestion and sequenced for an additional verification. The resulting
plasmids containing siRNA sequences for FUT1/4 were referred as FUT1-1
siRNA, FUT1-2 siRNA, FUT4-1 siRNA and FUT4-2 siRNA, respectively.
2.3. Transient transfection
A431 cells were trypsinized and seeded onto 6- or 96-well plates. When cells
reached to 80% confluence, FUT1-1 siRNA, FUT1-2 siRNA, FUT4-1 siRNA or
FUT4-2 siRNA was transiently transfected into A431 cells using 400 ng of
plasmid and 2 μl of Lipofectamine™ Reagent and Plus™ Reagent following the
manufacturer's instructions (Invitrogen). The transfection reagent was removed
after 12 h and the cells were harvested after 48 h.
2.4. Semi-quantitative RT-PCR
Total RNA was extracted and purified from untransfected and transfected
cells using Trizol reagent (Invitrogen). The cDNAwas synthesized using RNA
PCR Kit (AMV) Ver 3.0 (Takara). Primers used for detecting the expression
profile of FUT genes in A431 cells were indicated in Table 1 [32]. PCR
reactions were carried as follows: initial denaturation at 94 °C for 4 min,
28 cycles of 94 °C for 50 s, 55–57 °C for 50 s, 72 °C for 50 s, and a final
extension for 10 min at 72 °C in a 50 μl reaction mixture containing 2 μl each
cDNA, 0.2 μM each primer, 0.2 mM dNTP, and 2 U of Taq DNA polymerase.
Fig. 1. The expression profile of FUT genes and suppression of FUT1/FUT4 gene
expression after transient transfection of siRNAs directed against these two genes
in A431 cells. Generation of siRNA plasmids and extraction of total RNA siRNA
was performed as described in “Materials and methods”. Semi-quantitative RT-
PCRwas used to analyze the basal expression level of FUTs (FUT1, FUT2, FUT3,
FUT4, FUT5, FUT6, FUT7 and FUT9) and FUT1/FUT4 gene expression after
transient transfection of two FUT1 siRNA plasmids (FUT1-1 siRNA and FUT1-2
siRNA) and twoFUT4 siRNAplasmids (FUT4-1 siRNAand FUT4-2 siRNA). RT-
PCR products were identified on 1% agarose gel and the band density was
analyzed. (A) FUT mRNAs in A431 cells; (B) FUT1 mRNA expression after
FUT1 siRNA transfection; (C) Relative density of FUT1 mRNA vs. β-actin
mRNA. ⁎⁎, pb0.01; (D) FUT4mRNAexpression after FUT4 siRNA transfection;
(E) Relative density of FUT4 mRNA vs. β-actin mRNA. ⁎⁎, pb0.01. Control,
untransfected cells; FUT1-1, -2 and FUT4-1, -2 siRNA, cells transfected with
siRNAs directed against FUT1 and FUT4.
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gel electrophoresis, and the bands were then visualized by ethidium bromide
staining, followed by analysis with Labworks 4.6 (UVP. Inc). Beta-actin
expression was detected as the internal control, and the primers of proliferation
cell nuclear antigen (PCNA) were used to detect the PCNA gene expression
(Table 1).
2.5. Immunofluorescence staining
Forty-eight hours after transfection, the cells grown on the coverslips were
fixed in 4% paraformaldehyde for 15 min after washing with PBS. In FUT1/4
assay, cells were permeabilized with 0.1% Triton-PBS for 10 min at room
temperature. After blocking with complete serum for 2 h at 4 °C, goat anti-FUT1
antibody (1:100), goat anti-FUT4 antibody (1:100, Santa Cruz) or mouse anti-
LeY antibody (BG-8, 1:100, Signet Laboratories) was applied to incubate with
the slide overnight at 4 °C. Image was captured after incubation of cells with
FITC-conjugated mouse anti-goat IgG (1:100) for FUT1/4 and PE-conjugated
rat anti-mouse IgM (1:100, Santa Cruz) for LeY for 1 h using Olympus BX51
microscope (Japan).
2.6. Flow cytometry assay
Cells prepared as indicated above were gently trypsinized, and the single
cell suspension was collected. After washing with PBS, 0.1% Triton-PBS was
added and incubated for 10 min at 4 °C in FUT1/4 assay. The cells were then
incubated with goat anti-FUT1 antibody (1:100), goat anti-FUT4 antibody
(1:100, Santa Cruz) or mouse anti-LeYantibody (1:100), anti-H type 2 antibody
(1:100, GlycoTech), anti-LeX antibody ((1:100, GlycoTech), anti-sLeX anti-
body ((1:100, GlycoTech), respectively, for 1 h at room temperature. Unbound
antibodies were removed by washing with PBS for three times at room
temperature. FITC-conjugated mouse anti-goat IgG (1:100) for FUT1/4 or PE-
conjugated rat anti-mouse IgM (1:100) for LeY, H type 2, LeX and sLeX was
then applied to incubate with the cells for 45 min at room temperature. The
unbound secondary antibody was discarded and the cell mixture was adjusted
to 500 μl with PBS for measurement in a FACScan flow cytometer.
2.7. Cell proliferation assay
Cells (2×104 cells/well) were seeded onto each well of the 96-well plates in
140 μl complete medium for 4 h before starvation of serum. Twenty-four hours
after starvation (cells reached to 80% confluence), transfection was performed as
described above. After transfection was terminated, cells were treated with or
without either mouse anti-LeY antibody (0.2 μg/well) or LeY–PAA–biotin
(0.1 μg/well, GlycoTech) for 3 or 24 h at 37 °C. Twenty μl of 5 mg/ml 3-(4, 5-
dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) (Sigma) was
introduced into each well. After incubation for 4 h at 37 °C, MTT-containing
medium was decanted. Cells were subsequently dissolved in 100 μl DMSO with
gentle shaking for 30 min at room temperature, followed by measurement of
absorbance at 490 nm. The test was repeated for three different times in
triplicate.
2.8. Western blotting
Total protein from the whole cell lysate was prepared and applied for
Western blotting. In brief, cells prepared as indicated were washed, with PBS
(pH 7.4) and incubated with lysis buffer (1% Triton X-100, 150 mM NaCl,
10 mM Tris, pH 7.4, 1 mM EDTA, 1 mM EGTA, pH 8.0, 0.2 mM Na3VO4,
0.2 mM phenylmethylsulfonyl fluoride, 0.5% Nonidet P-40) for 30 min on ice.
Cell lysates were clarified by centrifugation at 9000 ×g for 10 min, and the
supernatant was collected. Protein concentration was determined with
Coomassie Protein Assay Reagent (Bio-Rad) using bovine serum albumin as
a standard. Total protein (8–40 μg) from the whole cell lysate was separated by
8–12% SDS-PAGE mini-gel. Proteins separated in the gel were transferred
electrophoretically onto nitrocellulose membrane. After blocking with TTBS
(50 mM Tris–HCl, pH 7.5, 0.15 M NaCl, 0.1% Tween-20) containing 5% fat-
free dry milk for 2 h, the membrane was incubated with specific monoclonal
antibodies directed against PCNA (1:1000), EGFR (1:1000), phosphorylatedEGFR (pEGFR) (1:500), phosphorylated ERK 1/2 (pERK1/2) (1:1000), or
phosphorylated tyrosine (pTyr) (1:1000,Transduction Laboratories) overnight
at 4 °C. Anti-β actin antibody (Santa Cruz) was used to confirm the equal
loading. After washing with TTBS three times, 5 min each, the membrane was
incubated with horseradish peroxidase (HRP)-conjugated anti-mouse antibody
(1:1000, Santa Cruz) for 1 h at 37 °C. The membrane was then developed using
an enhanced chemiluminescence (ECL) detection system (Amersham).
2.9. Xenograft cancer model
Female nude mice (Balb/c-nu/nu) were from Lab Animal Center in Dalian
Medical University (PR China). All experimental procedures involving animals
were conformed to the Experimental Animal Management Regulations of
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sterile conditions during the entire experimental period. On the 1st experimental
day, A431 cells (2×106) suspended in 0.2 ml PBS were injected into the right
flank subcutaneously. On the next day, FUT1-1 siRNA, FUT4-1 siRNA or
empty vector (150 μg DNA/mouse), and PBS were injected at the tumor cell
inoculation sites. Treatment was repeated every 48 h. Tumor volume was
measured by Vernier calipers every five days from the 5th day till the 25th day
after tumor inoculation. The tumor volume was computed according to the
formula (volume=length×width2×0.5). At the end of the experiment (the 25th
day), the tumor mass was weighed.
2.10. Immunohistochemistry staining of LeY in xenograft tumors
Each excised tumor tissue was fixed in 10% formalin for 24 h, embedded in
paraffin, and processed into 5 μm sections. For immunohistochemical analysis
of LeYexpression, slides were incubated overnight at 60 °C, deparaffinized, and
rehydrated using standard techniques. Tissue slides were blocked for 1 h at
37 °C with complete serum, then incubated overnight at 4 °C with mouse anti-
LeYantibody (1:100). LeY immunostaining was performed using avidin–biotin
peroxidase complex kit (Santa Cruz). Image was captured using Olympus BX51
microscope.
2.11. Statistical analysis
All data were analyzed statistically by Student's t test, with pb0.05
considered to be significant. Data were expressed as means±standard deviation.3. Results
3.1. Expression profile of FUT genes in A431 cells and
inhibition of FUT1/4 expression by their siRNAs
The expression profile of α1, 2- and α1, 3/4-FUT genes in
A431 cells was detected by semi-quantitative RT-PCR. Results
revealed that FUT1, FUT4, FUT5 and FUT9 were all strongly
expressed with FUT1 and FUT4 exhibiting greatest expression
(Fig. 1A, lanes 1, 4, 5 and 8), whereas the expression of FUT2,
FUT3 and FUT6 was low (Fig. 1A, lanes 2, 3 and 6). FUT7
expression was not detectable (Fig. 1A, lane 7).
The acceptor of FUT5 is a sialyl α2, 3-GalNAc-R, and FUT9.
Considering that the synthesis of LeY is mainly regulated by
FUT1 and FUT4, siRNA plasmids designed to target FUT1
(FUT1-1 siRNA and FUT1-2 siRNA) and FUT4 (FUT4-1
siRNA and FUT4-2 siRNA) were developed. Semi-quantitative
RT-PCR detection found that the expression of FUT1 (Fig. 1B,Fig. 2. siRNAs targeting FUT1/FUT4 inhibit expression of FUT1, FUT4 and
LeY. Two FUT1 siRNA plasmids (FUT1-1 siRNA and FUT1-2 siRNA) and two
FUT4 siRNA plasmids (FUT4-1 siRNA and FUT4-2 siRNA) were transfected
into A431 cells. Cells grown on the coverslips were used for immunofluores-
cence staining (A, B) or suspended cells for flow cytometry assay (C, D) as
described in “Materials and methods”. After incubation separately with
antibodies directed against FUT1 and FUT4 or LeY, respectively, FITC-
conjugated IgG or PE-conjugated IgM was used to determine the expression
level of FUT1, FUT4, or LeY. Immunofluorescence staining was used to detect
the expression intensity of (A) FUT1 (a–c), FUT4 (d–f), and (B) LeY,
respectively. Magnification, ×400. Flow cytometry was used to examine the
expression level of FUT1 (C-a), FUT4 (D-a), LeY or H type 2 in FUT1/FUT4
knocking down cells (b, c of C and D). Control, untransfected cells; FUT1-1, -2
and FUT4-1, -2 siRNA, cells transfected with siRNAs directed against FUT1 or
FUT4; Negative, cells incubated with secondary antibody only to serve as an
isotype control.
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row) genes was dramatically decreased by their relative siRNAs
in comparison to untransfected controls (top rows, lane 1 of B
and D) (pb0.01). Relative density analysis of FUT1 (Fig. 1C) or
FUT4 (Fig. 1E) gene expression vs. their internal control β-actin
expression indicated FUT1 gene expression was decreased
4.46-fold with FUT1-1 siRNA and 6.06-fold with FUT1-2
siRNA; and that of FUT4 was reduced 4.31-fold with FUT4-1
siRNA and 5.88-fold with FUT4-2 siRNA.3.2. Transient transfection of siRNAs of FUT1/4 decreases the
expression of both enzymes and LeY
To detect the protein expression level of FUT1/4 and LeY in
the cells, immunofluorescence staining and flow cytometry
were employed. Immunofluorescence staining revealed that the
protein expression level of FUT1/4 (Fig. 2A) was much lower in
siRNA-transfected A431 cells (b, c, e, and f) in comparison to
untransfected controls (a and d). Results indicate that these
siRNAs effectively interfere with the enzyme expression of both
FUT1 and FUT4 in vitro. The inhibitory effect on LeY expres-
sion level was also seen as detected by immunofluorescence
analysis. The fluorescence intensity of LeY in untransfected
control cells (Fig. 2B, a) was much stronger than that in FUT1
(b and c) and FUT4 (e and f) knocking down cells.
Flow cytometry studies showed the protein level of FUT1
(Fig. 2C, a), FUT4 (Fig. 2D, a) and LeY (b of C and D) was
significantly decreased in siRNA transfected A431 cells in
comparison to untransfected controls (Fig. 2C, D). No signif-
icant changes of H type 2 (Fig. 2C and D, c) and LeX (not
shown) was seen in cells with FUT1 and FUT4 knockdown. No
alterations in the sLeX expression were detected in FUT1 or
FUT4 siRNAs transfected cells (data not shown). These results
suggests that siRNAs of FUT1 and FUT4 strongly silence the
expression of their target enzymes and significantly prevent the
synthesis of LeY antigen.
3.3. Knocking down FUT1/4 expression inhibits cell
proliferation
To study the impact of down-regulating FUT1/4 expression
on cell proliferation, MTT assay was employed. The number of
proliferated cells was determined by measuring the absorbance
at a wavelength of 490 nm. Cell proliferation in FUT1 knocking
down cells was reduced 1.95–2.02-fold (Fig. 3A, lanes 4 and 6),
and 1.55–1.58-fold in FUT4 knocking down cells (Fig. 3A,
lanes 8 and 10) in comparison to the untransfected control cells
(Fig. 3A, lane 1). No significant difference in the proliferation
rate was seen between the empty vector-transfected and untrans-
fected cells (Fig. 3A, lane 2 vs. 1). The addition of anti-LeY
antibody exerted the inhibitory effect on cell proliferationFig. 3. Knocking down FUT1/4 gene inhibits cell proliferation after transient
transfection of siRNAs. FUT1/4 expressionwas decreased by transient transfection
of cells with their specific targeting siRNAs as described in “Materials and
methods”. Cell proliferation was determined by MTT assay (A) and PCNA
expression was detected by RT-PCR (B) and Western blotting (C). (A) Cells
differently treated were incubated with MTT to perform cell growth analysis. Data
presented here were representative ofmean values from three separate experiments
in triplicate. ⁎, pb0.05; ⁎⁎, pb0.01; (B) Total RNAwas isolated and purified from
cells prepared as indicated. After generating cDNAwith the purified RNA, PCNA
gene expression was detected by RT-PCR using β-actin as an internal control.
Relative density of PCNAmRNA vs.β-actin mRNAwas shown as bar graphs. ⁎⁎,
pb0.01; (C) Western blotting was adopted to examine PCNA protein expression
using β-actin protein expression as a loading control. Control, untransfected cells;
Vector, empty vector-transfected cells; LeY antibody, untransfected cells treated
with anti-LeYantibody; FUT1-1, -2 and FUT4-1, -2 siRNA, cells transfected with
siRNAs directed against FUT1 or FUT4; FUT1-1, -2 and FUT4-1, -2+LeY, cells
transfected with siRNAs were treated with LeYoligosaccharide.
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FUT4 knocking down cells partially reversed the inhibitory
effect of these siRNAs on cell proliferation (Fig. 3A, lane 5 vs.
4, 7 vs. 6, 9 vs. 8 and 11 vs. 10). This indicates that silencing of
FUT1/4 may prevent cell proliferation by downregulating LeY
expression.
PCNA is a commonly used marker to detect cell prolifera-
tion. The difference in PCNA expression among these cells
prepared as indicated above was measured by semi-quantitative
RT-PCR (Fig. 3B) and Western blotting (Fig. 3C). Consistent
with the results obtained from MTT assay, expression of PCNA
gene (B) and protein (C) was significantly decreased in the cells
transfected with siRNAs of FUT1 or FUT4. The expression ofFig. 4. Knocking down the expression of FUT1-1/FUT4-1 decreases xenograft A431
DNAs of FUT1-1 siRNA, FUT4-1 siRNA, empty vector, or PBS (control). The anim
xenograft tumor on day 25. Arrows indicate the location of tumors; Tumor volume (B
groups; (D) Immunohistochemistry staining of LeYexpression in excised xenograft tu
×200. Control, Vector, FUT1-1 siRNA or FUT4-1 siRNA represents tumor samp
respectively.PCNA gene was decreased 3.07–3.08-fold (Fig. 3B, lanes 2 and
3 vs.1 in a, lanes 2 and 3 vs. 1 in b) in FUT1 knockdown cells,
and 3.63–3.75-fold in cells when FUT4 was suppressed (Fig.
3B, lanes 5 and 6 vs. 4 in a, lanes 2 and 3 vs. 1 in c). The protein
expression level of PCNAwas decreased correspondingly in the
cells with reduced FUT1 (Fig. 3C, lanes 2 and 3 vs. 1) or FUT4
(Fig. 3C, lanes 5 and 6 vs. 4).
3.4. Knocking down FUT1/4 decreases the growth of A431
xenograft tumor in nude mice
siRNA plasmids directed against FUT1 or FUT4 down-
regulated the synthesis of LeYand inhibited cell proliferation intumor growth in nude mice. A431 cells xenograft nude mice were injected with
al assay was carried out for 25 days. (A) Display of sacrificed nude mice with
) and tumor mass curves (C) were generated with data from 6–8 mice in different
mors. Arrows indicate the expression of LeY in different groups. Magnification,
le from PBS, empty vector, FUT1-1 siRNA or FUT4-1 siRNA treated mice,
Fig. 5. Decrease of FUT1/FUT4 expression inhibits EGFR/MAPK signaling
pathway. Total proteinwas isolated from thewhole cell lysate after stimulationwith
EGF for 10 min. Eight to 40 μg total protein from different cells prepared as
indicated in “Materials and methods” was separated using an 8–12% SDS-PAGE
mini-gel, the proteinwas transferred onto nitrocellulosemembrane. The expression
and phosphorylation of EGFR, ERK1/2 and tyrosine kinase was detected with
antibody directed against EGFR (top row), pEGFR (second row), pERK1/2 (third
row) and pTyr (fourth row).
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siRNAs on tumor growth in vivo and the impact of them on LeY
expression in tumors, A431 cells were inoculated into the nude
mice. After local injection of siRNA (FUT1-1 siRNA, FUT4-1
siRNA), empty vector or PBS (control) every other day for
25 days at the A431 cells-inoculated site, tumor volume and
tumor weight were measured and recorded. Both FUT1-1
siRNA and FUT4-1 siRNA greatly impeded tumor growth
(Fig. 4A–C). At the end point, compared to the PBS or empty
vector-treated group, FUT1-1 siRNA reduced tumor volume
and tumor mass 1.95-fold (B) and 1.82-fold (C), respectively;
FUT4-1 siRNA reduced tumor volume and tumor mass by
1.72-fold (B) and 1.89-fold (C), respectively (pb 0.01).
The expression of LeY in the excised tumor tissues was
detected by immunohistochemistry staining. Four tumor sam-
ples were randomly selected from 4 experimental groups and
applied for immunohistochemical analysis using anti-LeY anti-
body. Results showed that LeY expression level was decreased
in tumors treated with siRNA plasmids directed against either
FUT1 (Fig. 4D, c) or FUT4 (d) in comparison to that in PBS-
treated- or empty vector-treated ones (a and b).
3.5. Knocking down FUT1/4 expression decreases the tyrosine
phosphorylation of EGF-mediated EGFR/MAPK
To study whether the decreased FUT1/4 expression affects
EGFR/MAPK signaling pathway, tyrosine phosphorylation of
EGFR and ERK1/2 was assessed by Western blotting. After
stimulation with EGF (100 ng/ml) for 10 min, antibodies
directed against EGFR, pEGFR and pERK1/2 were used to
probe the cell lysate prepared as described above. As expected,
the significant reduction in the phosphorylation of EGFR
(Fig. 5, second row) and ERK1/2 (third row) was found in FUT1
(lanes 2 and 3 vs. 1) and FUT4 (lanes 5 and 6 vs. 4) knocking
down cells. In addition, anti-pTyr antibody was selected to
further assess the changes of phosphorylated tyrosine kinase
(fourth row).4. Discussion
Abnormal elevation in the expression of LeY are seen in
many cancers and correlates with the malignancy of cancers. To
develop the potential therapeutic approaches in the treatment of
LeY-positive cancers, much attention has focused on blocking
LeY function with anti-LeY antibodies [39–41], but little
attention has been paid to generate a method by inhibiting the
synthesis of LeY to prevent cancer growth.
LeY synthesis can be regulated at the transcriptional level by
FUT1/4 genes [23,42]. The overexpression of FUT1/4 elevates
the synthesis of LeY [35,22]. Among the eight α1, 2- and α1 3/
4-FUT genes, FUT1 and FUT4 are predominant FUTs
expressed in A431 cells. Although the strong expression of
FUT5 and FUT9 was also seen in A431 cells, the acceptor of
Acceptor of FUT5 is sialyl α2, 3-GalNAc-R which does not
belong to type 2 epitope, and FUT9 exhibits more efficient
activity for the synthesis of LeX [43]. We hypothesized that
knocking down the expression of FUT1 and FUT4 genes would
more specifically decrease LeY synthesis in A431 cells and
inhibit tumor growth. In this study, we have developed siRNAs
to specifically knock down the expression of FUT1/4 genes.
Their impact on the synthesis of LeYand tumor growth was also
studied. We found that the gene and protein expression levels of
FUT1/4 were significantly reduced by the siRNA transfection.
These siRNAs also showed significantly inhibitory effects on
tumor growth both in vitro and in vivo models. These results
indicate that inhibition of either FUT1 or FUT4 down-regulates
the synthesis of LeY and decreases neoplastic cell proliferation
and tumor growth.
The α1, 2-fucosylation and α1, 3-fucosylation are crucial for
the synthesis of LeY which correlates to cancer malignancy.
The expression of Fucα1→2Galβ motif is related to the cancer
progression in colon [28,44]. Goupille et al. [45] found that
transfection of rat colon carcinoma cells with the antisense
oligonucleotides of FUT1 gene reduced the cancer malignancy
in syngeneic animals. Our results showed that treatment with
FUT1 RNAi plasmids decreased the synthesis of LeY and
reduced neoplastic cell proliferation. Alpha 1, 3-fucosylation of
LeY is mainly regulated by FUT4 [31]. Increased FUT4 has
been found in two ovarian cell lines which highly express LeY
and LeX [22]. The overexpression of FUT4 is associated with
the progression of ovarian cancer. Both FUT4 and LeY are also
increased during the early human embryo development [1,46],
and the elevated LeY, a fetooncogene, probably correlates with
the overexpressed FUT4. Our data showed that FUT4 RNAi
plasmids significantly decreased the synthesis of LeY. FUT4
has two different transcription initiation sites that produce long-
and short-form mRNAs of FUT4, respectively. The expression
level of long-form mRNA is higher than the short-form
transcript in cancer cell lines [31]. The interference sequences
of FUT4 in our study covered not only the short-form but also
the long-form mRNAs of FUT4 which produced a complete
inhibition on FUT4 function. We have also detected the
expression of other LeY-related fucosylated antigens, such as
H type 2, LeX and sLeX. No significant difference was found
on H type 2 and LeX, as well as no change on sLeX when the
294 Z. Zhang et al. / Biochimica et Biophysica Acta 1783 (2008) 287–296expression of FUT1 or FUT4 was reduced. It is possible that
FUT9 plays a more important role on LeX though FUT4 also
affects the synthesis of LeX. FUT7 is responsible for synthesis
of sLeX [18]. In our study, no expression of FUT7 was detected
in A431 cells. In order to understand detailed mechanism of
regulation of fucosylated sugar chains by specific fucosyltrans-
ferases, further study needs to be explored.
LeY expression is related to the cancer growth and metastatic
potential. The higher expression level of LeYis linked to themore
progressive clinical grade of endometrial carcinoma [6]. Sup-
pression of the specific fucosyltransferases by RNAi technique
will not only help to elucidate the function of fucosylated antigens
in carcinogenesis, but also provide a new approach for the
treatment of cancers through inhibiting fucosylated antigen
synthesis. We found that knockdown of FUT1/4 expression
reduced the synthesis of LeYand inhibited cancer growth in both
in vitro and in vivo models. Functional blockage of LeY antigen
and injection of anti-LeYantibody intoA431 xenograft nudemice
induced the significant reduction of cancer weight and volume
[39,40]. In this study, we found that directly interfering LeY
synthesis by disrupting FUT1/4 gene expression with RNAi
technique inhibited neoplastic cell proliferation and tumor
growth. siRNA is a small molecule which is easier to access to
its specific target cells in comparison with the antibody. It may
also have fewer side effects than the treatment with an antibody.
siRNA-mediated inhibition of LeY synthesis would be an
effective novel approach for anticancer treatment.
LeY is mainly distributed on the plasma membrane of can-
cer cells [42], and carried by different glycolipids [47] and
glycoproteins, such as CD44v6 (30), EGFR [48] and MUC6
[9,49], which are related to carcinogenesis. Using ABL364 and
IGN311 (antibodies directed against LeY antigen), EGFR
activation is prevented and neoplastic cell growth is inhibited
[39,40]. The activation was also decreased by FUT1 siRNAs or
FUT4 siRNAs, indicating that down-regulation of LeY may
inhibit EGFR activation, consequently influencing EGFR/
MAPK signaling pathway mediated cancer cell proliferation.
The other LeY-containing glycoconjugates mentioned above
may also be changed in FUT1/4 knocking down cells, and this
issue deserves further investigation.
In addition to the stimulatory effect of LeYon EGFR/MAPK
signaling and tumor growth, LeY may also function as an
adhesive molecule in cancer cell adhesion and migration. We
have previously shown that LeY was stage-specifically
expressed during embryo development. Injection of anti-LeY
antibody into the uterus of pregnant mouse or preincubation of
the embryo with anti-LeYantibody impaired the implantation of
embryo to the uterus. These treatments also reduced the
secretion and expression of matrix metalloproteinase (MMPs)
[1,24,50]. LeYexpression level is increased in the angiogenesis-
rich rheumatoid arthritis compared with that in nonangiogenic
osteoarthritis. It suggests that LeY may serve as an angiogenic
mediator [51]. Accumulated evidence suggests that LeY not
only plays a role in the inflammatory angiogenesis, but also
regulates the cancer angiogenesis and promotes tumor growth
and metastasis. Therefore, it is important to inhibit LeY
synthesis in anti-inflammation and anticancer treatment.In summary, our current study demonstrates that FUT1/4
siRNA plasmids down-regulate LeY synthesis level, inhibit
EGFR activation, and effectively reduce tumor growth. To our
knowledge, this is the first report to study the suppression of the
expression of LeY prevention of the tumor cell proliferation by
knockdown of FUT1/4 expression with RNAi technique. Our
results also implicate that the siRNAs of FUT1/4 could be a
potential therapeutic agent for treatment of human LeY-
expressing cancers.
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